Efimosfermin is a long-acting engineered variant of FGF21 designed to have a prolonged half-life, the authors noted, and has ...

The president wants a the most-favored-nation pricing model. But the U.S. drug industry is offering a host of reasons why ...

A Houston-based compounding pharmacy has fired back against a lawsuit filed by the pharmaceutical giant that makes Mounjaro ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Lipid management for woman requires personalized care that considers sex-specific conditions across the reproductive lifespan ...

India has officially approved and launched Mounjaro (tirzepatide), a groundbreaking injectable medication for the treatment of Type 2 diabetes and obesity. Developed by Eli Lilly and Company, the drug ...

By Rishika Sadam (Reuters) -Indian contract drug manufacturer OneSource Specialty Pharma expects strong growth in its order book over the next three years, driven by the global boom in weight-loss ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Lilly Sabri used to hope at least three people would show up to her Pilates classes, now she has six million YouTube ...